Liver Int2011 . .. , 31(Suppl 2) : 1-3.
Shah HA,Jafri W,Malik I .1997 .Hepatitis C virus genotypes and chronic liver disease in Pakistan. J GastroenterolHepatol, 12 : 758-61.
Idrees M,Riazuddin S.,Bousquet V,Delarocque-Astagneau E .2008 .HCV Surveillance Steering Committee Hepatitis C virus genotype 3 and the risk of severe liver disease in a large population of drug users in France. J Med Virol2010;, 82 : 1647-54.
.2014 .. JAMA Intern Med, 174 : 204-12.
Wang C,Valera L,Jia L,Kirk MJ,Gao M,Fridell RA. . .In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A. , 57 : 611-3.
.2013 .. N Engl J Med, 368 : 1878-87.
Nelson DR,Cooper JN,Lalezari JP . .All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. J Hepatol2015, 61(4) : 1127-35.
Sulkowski MS,Gardiner DF,Rodriguez-Torres M .2014 .Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med, 370(3) : 211-21.
Umer M,Iqbal M .2016 .Hepatitis C virus prevalence and genotype distribution in Pakistan: comprehensive review of recent data. World J Gastroenterol, 22(4) : 1684.
Sulkowski MS,Jacobson IM,Nelson DR .2014 .Daclatasvir plus sofosbuvir for HCV infection. N Engl J Med, 370(16) : 1560.
.2018 .HCV treatment initiation in persons with chronic kidney disease in the directly acting antiviral agents era: results from ERCHIVES. Liver Int, 38(8) : 1411-7.
.2018 .Daclatasvir and asunaprevir inhemodialysis patients with hepatitis C virus infection: a nationwideretrospective study in Japan. J Gastroenterol, 53(1) : 119-28.
Atsukawa M,Tsubota A,Toyoda H,Takaguchi K,Nakamuta M,Watanabe T . .The efficacy andsafety of glecaprevir plus pibrentasvir in 141 patients with severe renalimpairment: a prospective, multicenter study. , : .
.2019 .. Aliment PharmacolTher, 49(9) : 1230-41.
Atsukawa M,Tsubota A,Koushima Y,Ikegami T,Watanabe K,Shimada N .2017 .Efficacy and safety of ombitasvir/ paritaprevir/ritonavir in dialysis patients with genotype 1b chronic hepatitis C. Hepatol Res, 47(13) : 1429-37.
Li T,Qu Y,Guo Y,Wang Y,Wang L Y .2017 .Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4- 5 chronic kidney disease: a meta-analysis. Liver Int, 37(7) : 974-81.
Agarwal SK,Bagchi S,Yadav RK .2017 .Hemodialysis patients treated for hepatitis C using a sofosbuvir-based regimen. Kidney Int Rep, 2(5) : 831-5.
Safety .2014 .Anti-viral Efficacy and Pharmacokinetics (pk) of Sofosbuvir (sof) in patients with severe renal impairment. Hepatology, 60 : 667A.
Desnoyer A,Pospai D,Lê MP,Gervais A,Heurgué-Berlot A,Laradi A .2016 .Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. J Hepatol, 65(1) : 40-7.
Ram BK,Frank C,Adam P,Cynthia L,Maria H,Lennox J .2015 .Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of hepatitis C in patients with end stage renal disease. J Hepatol, 63(3) : 763.